Log in
NYSE:MNK

Mallinckrodt Stock Forecast, Price & News

Lowest-Rated Stocks  
$0.14
-0.01 (-6.62 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.13
Now: $0.14▼
$0.16
50-Day Range
$0.14
MA: $0.80▼
$1.41
52-Week Range
$0.75
Now: $0.14▼
$6.42
Volume2.09 million shs
Average Volume6.49 million shs
Market Capitalization$11.93 million
P/E RatioN/A
Dividend YieldN/A
Beta3.06
Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
Read More
Mallinckrodt logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.8Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.96 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:MNK
Previous Symbol
CUSIPN/A
CIK1567892
Webwww.mallinckrodt.com
Phone(531) 696-0000
Employees3,400

Debt

Debt-to-Equity Ratio5.39
Current Ratio1.48
Quick Ratio1.23

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio0.02
P/E Growth0.01

Sales & Book Value

Annual Sales$3.16 billion
Price / Sales0.00
Cash Flow$2.82 per share
Price / Cash Flow0.05
Book Value$23.08 per share
Price / Book0.01

Profitability

EPS (Most Recent Fiscal Year)$8.88
Net Income$-996,500,000.00
Net Margins-89.94%
Return on Equity34.26%
Return on Assets6.66%

Miscellaneous

Outstanding Shares84,589,000
Market Cap$11.93 million
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$0.14
-0.01 (-6.62 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Mallinckrodt (NYSE:MNK) Frequently Asked Questions

How has Mallinckrodt's stock been impacted by COVID-19 (Coronavirus)?

Mallinckrodt's stock was trading at $3.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MNK stock has decreased by 95.4% and is now trading at $0.1410.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Mallinckrodt?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 4 sell ratings and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Mallinckrodt.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Mallinckrodt.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt plc (NYSE:MNK) released its earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.34 by $0.55. The firm earned $700.90 million during the quarter, compared to the consensus estimate of $630.19 million. Mallinckrodt had a positive return on equity of 34.26% and a negative net margin of 89.94%. The firm's revenue for the quarter was down 14.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.53 earnings per share.
View Mallinckrodt's earnings history.

What price target have analysts set for MNK?

10 equities research analysts have issued 1-year target prices for Mallinckrodt's shares. Their forecasts range from $1.50 to $4.00. On average, they expect Mallinckrodt's share price to reach $2.70 in the next twelve months. This suggests a possible upside of 1,814.9% from the stock's current price.
View analysts' price targets for Mallinckrodt.

Who are some of Mallinckrodt's key competitors?

Some companies that are related to Mallinckrodt include Onconova Therapeutics (ONTX), CV Sciences (CVSI), SCYNEXIS (SCYX), Zomedica (ZOM), Cumberland Pharmaceuticals (CPIX), Moleculin Biotech (MBRX), KemPharm (KMPH), Forward Pharma A/S (FWP), KemPharm (KMPH), Cocrystal Pharma (COCP), Addex Therapeutics (ADDXF), CohBar (CWBR), Ceapro (CRPOF), Kazia Therapeutics (KZIA) and PainReform (PRFX).
View all competitors.

What other stocks do shareholders of Mallinckrodt own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), (CELG) and Advanced Micro Devices (AMD).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the following people:
  • Mark C. Trudeau, President, Chief Executive Officer & Director
  • Bryan M. Reasons, Chief Financial Officer & Executive Vice President
  • Steven Joseph Romano, Chief Scientific Officer & Executive VP
  • Babatunde Adekunle Otulana, Chief Medical Officer & Senior Vice President
  • Michele Robertson, Chief Compliance Officer & Senior Vice President

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

Who are Mallinckrodt's major shareholders?

Mallinckrodt's stock is owned by a number of retail and institutional investors. Top institutional shareholders include LSV Asset Management (1.28%) and KBC Group NV (0.20%). Company insiders that own Mallinckrodt stock include Bryan M Reasons and Mark Trudeau.
View institutional ownership trends for Mallinckrodt.

Which institutional investors are selling Mallinckrodt stock?

MNK stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management.
View insider buying and selling activity for Mallinckrodt.

Which institutional investors are buying Mallinckrodt stock?

MNK stock was purchased by a variety of institutional investors in the last quarter, including KBC Group NV. Company insiders that have bought Mallinckrodt stock in the last two years include Bryan M Reasons, and Mark Trudeau.
View insider buying and selling activity for Mallinckrodt.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $0.14.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $11.93 million and generates $3.16 billion in revenue each year. The company earns $-996,500,000.00 in net income (profit) each year or $8.88 on an earnings per share basis. Mallinckrodt employs 3,400 workers across the globe.

What is Mallinckrodt's official website?

The official website for Mallinckrodt is www.mallinckrodt.com.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is COLLEGE BUSINESS & TECHNOLOGY PARK CRUISERATH BLANCHARDSTOWN, DUBLIN 15 L2, D15. The company can be reached via phone at (531) 696-0000 or via email at [email protected]

This page was last updated on 10/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.